Breaking News

MEDIAN Technologies Wins Phase III Imaging Project

By Kristin Brooks | January 30, 2014

To provide imaging services for multi-site oncology trial

MEDIAN Technologies has been selected to provide imaging services in a Phase III trial sponsored by a U.S.-based specialty pharmaceutical company, in a transaction valued at $870,400.
 
Imaging data will be acquired from approximately 24 clinical sites in Europe and Asia, which is expected to enroll 200 patients. MEDIAN will provide clinical site qualification and training, image data collection, quality control, centralized data storage, and Independent Central Review (ICR) services using its Lesion Management Solutions (LMS) software. LMS is a suite of software modules for the review of images and quantitative assessment of response to therapy in trials.
 
"We are proud of this new project award and enthusiastic about working with both our CRO strategic partner and the specialty pharmaceutical company sponsor on this Phase III study," said Fredrik Brag, chairman and chief executive officer of MEDIAN Technologies. "This award further reinforces the value of our alliance and strengthens our commercial positioning."

Related Compliance:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research